Levofloxacin is FDA-approved for the treatment of nosocomial pneumonia, community-acquired pneumonia, acute bacterial rhinosinusitis, acute bacterial exacerbation of chronic bronchitis, acute bacterial prostatitis, acute pyelonephritis, urinary tract infection, skin or skin structure infections, prophylaxis, and treatment of plaque due to Yersinia pestis, and to reduce the incidence of disease progression of inhalational anthrax. It is in the fluoroquinolone class of medications. This activity will highlight the indications, mechanism of action, adverse event profile, contraindication, monitoring, toxicity, and relevant interactions pertinent for healthcare team members in treating patients with bacterial infections.

**Objectives:**
- Identify the mechanism of action of levofloxacin.
- Identify the indications of levofloxacin.
-  Recognize the adverse effects of levofloxacin.
- Outline interprofessional team strategies for improving care coordination and communication to advance levofloxacin and improve outcomes.